Aristea: An AstraZeneca spinout scores a buyout option from Arena
The potential acquisition deal marks a fast turnaround for Aristea, which is one of several biotechs formed from programs AstraZeneca decided not to advance internally.
Read full article »
Aristea is a California-based biotechnology firm that develops and commercializes novel therapies for the treatment of inflammatory diseases.
Read more